GenomeDx Expands Insurance Coverage for Decipher® Prostate Cancer Test Through Contract with Prime Health Services
PR Newswire Association LLC |
The Decipher Prostate Cancer Classifier directly measures a patient's biological risk of developing metastatic prostate cancer. Together with existing coverage from other networks, the contract brings coverage of the Decipher prostate cancer test to nearly 120 million lives.
"With a robust package of clinical data related to the performance and clinical utility of Decipher, we've shown that the test not only outperforms other tools for predicting cancer metastasis in men who have had a radical prostatectomy, but that this information also impacts treatment decisions in 30-40% of cases," said
About Decipher
Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about ordering the Decipher test please visit www.deciphertest.com.
About GenomeDx
GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in
About
Founded in 2001 and based in
SOURCE GenomeDx Biosciences
Wordcount: | 482 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News